Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02663518 · ClinicalTrials.gov registry record · Phase 1
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 249
- Enrollment target
NCT02663518: Clinical Trial Phase 1 study, sponsored by Pfizer.
NCT02663518 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 249 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (315% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02663518, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 249 participants
- Enrollment target
Study Summary
Multicenter, open-label, phase 1a/1b trial of PF-07901800 (TTI-621) in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.
Primary Outcome
An adverse event (AE) was any untoward medical occurrence in administered medicinal product, event need not necessarily have a causal relationship with product treatment or usage. A serious adverse event (SAE) was any untoward medical occurrence in a participant administered a medicinal or nutritional product (including pediatric formulas) at any dose that: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of hospitalization; resulted in persistent or si
Interventions
- DRUG PF-0791800 (TTI-621)
- DRUG PF-07901800 (TTI-621) plus Rituximab
- DRUG PF-07901800 (TTI-621) plus Nivolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 249 participants |
| Start Date | 2016-01-28 |
| Est. Completion | 2022-11-23 |
| Phase | Phase 1 |
Why NCT02663518 stopped before completion
NCT02663518 is an interventional study that assigns participants to a tested intervention. The registered 249 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (315% higher).
The record links to 0 conditions, and to 3 interventions - of which PF-0791800 (TTI-621) is the first listed.
NCT02663518 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02663518 about?
NCT02663518 is a clinical study titled "A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors". Multicenter, open-label, phase 1a/1b trial of PF-07901800 (TTI-621) in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.
What is the current status of trial NCT02663518?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 249 participants. The study started on 2016-01-28. Estimated completion is 2022-11-23.
What interventions are being tested in trial NCT02663518?
The interventions under investigation include: PF-0791800 (TTI-621) (DRUG), PF-07901800 (TTI-621) plus Rituximab (DRUG), PF-07901800 (TTI-621) plus Nivolumab (DRUG).
Who is sponsoring clinical trial NCT02663518?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02663518's enrollment target sits among peer trials
249 185th of 2000 higher than 1,816 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04628767 · 249 participants · Phase 2
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
- NCT05834907 · 249 participants · NA
Hands and Hearts Together
- NCT06067555 · 249 participants · Early Phase 1
Intradermal Influenza Vaccination
- NCT06588478 · 249 participants · Phase 2
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI